

# ELUCIDATING THE MECHANISM OF HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1) REGULATION IN KIDNEY

Junna Yamaguchi<sup>1</sup>, Tetsuhiro Tanaka<sup>1</sup>, Nobuaki Eto<sup>1, 2</sup>, Masaomi Nangaku<sup>1</sup>

<sup>1</sup>Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, <sup>2</sup>Kyowa Hakko Kirin

## Background and Objectives:

- HIF-1 plays a critical role in tubular cells of both acute and chronic ischemic kidney.
- Its protective role against tubular injury has been suggested and HIF activation is a potential therapeutic option in kidney diseases.
- We aimed to identify a novel gene involved in regulation of HIF-1 in hypoxia of the kidney, a final common pathway to end stage kidney disease.

## Methods:


- Microarray analysis of the renal cortex of chronic hypoxia model, rat renal artery stenosis (RAS) model (day3 and day7), was used as *in vivo* screening for potential HIF-1 regulating genes.
- HeLa cells transfected with shRNA plasmids against continuously up-regulated genes in RAS kidney compared to sham kidney were evaluated for potency of HIF-1 regulation.
- Acute and chronic rat hypoxic models were analysed for this gene's expression to localise and identify its role in kidney.
- To confirm its relation to hypoxia in cultured human renal tubular cells, RNAi treated HK-2 cells under hypoxic condition were examined for HIF-1 regulation.
- Pathways regulating this gene up-regulation under hypoxia and mechanism of HIF-1 regulation by this gene were investigated.

## Results:


### Fig1. Identification of HIF-1 upregulating genes

- 150 genes were extracted from microarray analysis.
- shRNA library experiment revealed CEBPD as the most promising HIF-1 regulator.

#### A. Immunoblot/ HeLa



#### B. HREluc/ HeLa



\*\*p < 0.01 by two-way ANOVA, post-Bonferroni's test


### CCAAT/enhancer-binding protein delta (CEBPD)

- transcription factor
- Leucine zipper DNA-binding protein
- exhibits cell-type specific roles: acute inflammatory response in macrophages, tumor suppressor in certain cancer cells, differentiation factor in adipocytes, etc.


### Fig2. CEBPD is expressed in tubular cells in acute and chronic hypoxic kidney.

#### RT-PCR (kidney cortex)


##### A. I/R injury




##### C. Remnant kidney (RK)




##### B. Cisplatin nephrotoxicity



##### D. RAS




#### Immunohistochemistry (anti-CEBPD Ab)




A. Ischemia-reperfusion (I/R) group: right nephrectomy and clamping of left renal artery and vein for 45 mins, sacrificed 24 hrs after operation. Control n=3, I/R n=5. (\*p < 0.05 vs control)  
 B. Cisplatin nephrotoxicity group: Cisplatin 6mg/kg ip, vehicle saline, sacrificed 3 days after treatment. Control n=5, Cisplatin n=6. (\*p < 0.05 vs control)  
 C. Remnant kidney (RK) group: right nephrectomy followed by ligation of the posterior and two of the anterior branches of the left renal artery, sacrificed at indicated times. Control n=5, RK1w n=5, RK4w n=5. (\*p < 0.05 vs control)  
 D. Renal artery stenosis (RAS): left renal artery clipped with U-shaped clip, sacrificed 7 days after treatment. Control n=5, RAS n=5. (\*\*p < 0.01 vs control).

### Fig3. CEBPD regulates HIF-1 in proximal tubular cells.


#### A. Immunoblot/ HK-2




#### C. RT-PCR/ HK-2



#### B. HREluc/ HK-2




#### D. RT-PCR/ HK-2





\*p < 0.05, \*\*p < 0.01 by two-way ANOVA, post-Bonferroni's test

### Fig4. Inflammation and hypoxia co-exist in tubulointerstitium.

#### A. Immunohistochemistry (ED-1)




#### B. RT-PCR (renal cortex)




\*p < 0.05, \*\*p < 0.01 vs control

### Fig5. IL-1β activates CEBPD/HIF-1 pathway even under normoxia.

#### A. Immunoblot/HK-2




#### B. Immunoblot/HK-2




### Fig6. CEBPD regulates HIF-1α at transcription level.


#### A. Human HIF-1α promoter assay/HK-2




#### B. ChIP/HK-2



#### A. growth factors, cytokines hypoxia



#### B. macrophage



Yamaguchi J, Tanaka T, Eto N, and Nangaku M: *Kidney Int*, Epub ahead of print

## Conclusion:

- We identified CEBPD as a novel HIF-1 upregulator in kidney.
- We identified CEBPD's expression in tubular cells in acute and chronic hypoxic kidney.
- We found a potential role of CEBPD as a crosslinker of inflammation and hypoxia via HIF-1.
- CEBPD is induced by NF-κB, which then regulates HIF-1α at transcription/post-transcription level.
- CEBPD/HIF-1 pathway is a potential therapeutic target in kidney disease.

## Reference:

- Kojima I, Tanaka T, Nangaku M: *Kidney Int* 75: 268-77, 2009
- Tanaka T, Kojima I, Nangaku M: *Am J Physiol Renal Physiol* 289: F1123-33, 2005

